sion. An experimental investigation in pigs. Anesthesiology 1995; 83:1283-92

- 2. Jensen K, Öhrström J, Cold GE, Astrup J: The effect of indomethacin on intracranial pressure, cerebral blood flow and cerebral metabolism in patients with severe head injury and intracranial hypertension. Acta Neurochir 1991; 108:116-21
- 3. Biestro AA, Alberti RA, Soca AE, Cancela M, Puppo CB, Borovich B: Use of indomethacin in brain-injured patients with cerebral perfusion pressure inpairment: Preliminary report. J Neurosurg 1995; 83:627-30
- 4. Dahl B, Bergholt B, Cold GE, Astrup J, Mosdal B, Jensen K, Kjærsgaard JO: CO₂ and indomethacin vasoreactivity in patients with head injury. Acta Neurochir (Wien) 138:265-73
- 5. Jensen K, Freundlich M, Bünemann L, Therkelsen K, Hansen H, Cold GE: The effect of indomethacin upon cerebral blood flow in

healthy volunteers. The influence of moderate hypoxia and hypercapnia. Acta Neurochir 1993; 124:114-9

- 6. Jensen K, Kjærgaard S, Malte E, Bünemann L, Therkelsen K, Knudsen F: Effect of graduated intravenous and standard rectal doses of indomethacin on cerebral blood flow in healthy volunteers. J Neurosurg Anesth 1996; 8:111-6
- 7. Bundgaard H, Jensen K, Cold GE, Bergholt B, Frederiksen R, Pless S: The effects of perioperative indomethacin on intracranial pressure (ICP), cerebral blood flow (CBF) and cerebral metabolism in patients subjected to craniotomy for cerebral tumors. J Neurosurg Anesth 1996; 8:273-9
- 8. Messick JM, Casement B, Sharbrough FW, Milde LN, Michenfelder JD, Sundt TM: Correlation of regional cerebral blood flow (rCBF) with EEG changes during isoflurane anesthesia for carotid endarterectomy: Critical rCBF. Anesthesiology 1987; 66:344-9

(Accepted for publication September 12, 1996.)

Anesthesiology 1996; 85:1500 - 1 © 1996 American Society of Anesthesiologists, Inc. Lippincott-Raven Publishers

In Reply:—The comment by Cold et al. to our article "Cerebral Vasoconstriction by Indomethacin in Intracranial Hypertension" addresses important problems within neuro-intensive care: Should post-traumatic brain swelling be treated with pharmacologic vasoconstriction? If so, what drug and dosage should be chosen? In our study of induced intracranial hypertension in piglets, we found that indomethacin reduced intracranial pressure (ICP) by constriction of precapillary resistance vessels only when cerebral blood flow (CBF) was reduced to a level where progressive changes in CavO₂, vpH, and electroencephalography occured, indicating ischemia. We concluded that our data did not support the use of indomethacin in patients with intracranial hypertension due to head injury. In their comment, Cold et al. refer to clinical publications not available at that time. Some of these are still in press, but we had the opportunity to review the manuscripts.

The study by Biestro *et al.*² included 10 patients with severe head injuries and raised ICP. The patients were given an indomethacin bolus (50 mg) followed by a continuous infusion (21.5 \pm 11.4 mg/h). The authors measured significant decreases in ICP and increases in cerebral perfusion pressure (CPP) during the treatment, but no data were given regarding CBF, CavO₂, vpH, electroencephalography, or other physiologic parameters. Four of the ten head-injured patients were reported dead, but no data regarding the cause or the time of death were presented.

In the study by Dahl *et al.*,³ physiologic parameters that included ICP, CPP, CBF, and CavO₂ were studied in 14 patients with head injuries (mean ICP 14.8 mmHg before treatment). The study compared the effect of a bolus indomethacin (30 mg intravenously) with that of induced hypocapnia. Indomethacin was found to decrease ICP and CBF and increase CavO₂ significantly. It is remarked by the authors that: "Although ischaemia evaluated from CBF, SvjO₂, and LOI (lactate/oxygen index) were indicated in individual cases after both hyperventilation and indomethacin, it was not reflected in outcome." However, the increase in ICP before treatment was very modest, and "patients in poor clinical condition indicating transtentorial herniation were excluded." There is no indication in the study

that a bolus injection of indomethacin had any beneficial effect on outcome.

Downloaded from http://asa2.silverchair.com/anesthesiology/article-pdf/85/6/1500/365543/0000542-199612000-00045.pdf by guest on 19 April 2024

In their letter, Cold et al. claim that, during continuous intravenous indomethacin treatment, "the ICP-reducing effect is sustained and the increase in AVDO2, the jugular venous lactate and EEG are transitory" and that they "find a low mortality of 10% in indomethacin treated severe head injury." We have been unable to find the data supporting these statements. In the report by Jensen et al.4 indomethacin was administered intravenously throughout a 7-h period. During this period, the decrease in global CBF and the increase in CavO₂ remained. At 7 h after start of infusion, ICP seemed to have returned close to pretreatment level (28 \pm 3 mmHg vs. 25 \pm 11 mmHg). There is a lack of information regarding physiologic parameters in patients with severe head injuries when indomethacin infusion is continued beyond 7 h. Cold et al. also said that "results in an experimental model of a focal mass expanding lesion in pigs cannot rightly be transferred to the pathophysiological events of severe human head injury." Although this is obviously true, it seems to us that the clinical experiences by Biestro et al.2 and Dahl et al.3 are in good agreement with our experimental study: indomethacin reduces increased ICP, but at the expense of decreased CBF and impending cerebral ischemia. We agree with Cold et al. that indomethacin is contraindicated in patients suffering from cardiac ischemia, renal insufficiency, gastric bleedings, and coagulation disorders. Unfortunately, patients with severe head trauma may, quite often, experience multi-organ failure, which may limit the clinical use of indomethacin even further.

In our opinion, cerebral vasoconstriction is only one of the components, though important, in the treatment of posttraumatic brain swelling. Our treatment concept was published recently.⁵ The concept aims at a reduction of ICP through decreased CBF and increased absorption of cerebral interstitial fluid. The latter is accomplished through reduction of intracapillary pressure by a combination of moderate precapillary vasoconstriction (DHE) and reduction of mean arterial blood pressure. We are currently reviewing our clinical results since 1989 that show that mortality in patients with closed head injuries has been almost eliminated, with no increase in the number of patients surviving in a vegetative state (Eker *et al.*, in preparation).

poxia and hypercap nn L, Therkelsen K standard rectal doses

hy volunteers. J Neuolt B, Frederiksen R

hacin on intracranial cerebral metabolism I tumors. J Neurosurg

V, Milde LN, Michencerebral blood flow mesthesia for caroud 1987; 66:344-9

12, 1996.)

ny beneficial effect on

ontinuous intravenous effect is sustained and ate and EEG are transi 10% in indomethacia inable to find the data ensen et al.4 indometh out a 7-h period. During the increase in CavO₁ emed to have returned 25 ± 11 mmHg). There parameters in patients n infusion is continued alts in an experimental pigs cannot rightly be of severe human head ms to us that the clinical ³ are in good agreement reduces increased ICP. mpending cerebral isch thacin is contraindicated

enal insufficiency, gastic ortunately, patients with tence multi-organ failure, thacin even further, is only one of the composit of posttraumatic brain shed recently. The concreased CBF and increased CBF and increased CBF and increased CBF and increased CBF and reduction of mean the particular of the properties of the properties of the particular concrease in the number of the patients with closed head on increase in the number of the patients with closed head on increase in the number of the patients with closed head of t

Although Cold *et al.* and our group seem to disagree partly regarding the clinical use of indomethacin, we share the view that pharmacologic vasoconstriction shows promise for the treatment of increased ICP. Probably, the optimal drug should combine a pronounced constriction of cerebral venous capacitance vessels and a moderate constriction of cerebral precapillary resistance vessels with no or insignificant effects in other vascular territories.

Fritiof Nilsson, M.D. Staff anesthesiologist Department of Anesthesia Malmö University Hospital Sven Björkman, Ph.D. Associate Professor Pharmaceutical Chemistry Hospital pharmacy Malmö University Hospital Ingmar Rosén, M.D., Ph.D. Professor Clinical Neurophysiology University Hospital, Lund Kenneth Messeter, M.D., Ph.D. Associate Professor Anesthesiology Head of Department Department of Anesthesia Malmö University Hospital S-20502 Malmö Sweden Carl-Henrik Nordström, M.D., Ph.D. Associate Professor Neurosurgery

Department of Neurosurgery University Hospital, Lund S-22185 Lund Sweden

References

1. Nilsson F, Björkman S, Rosén I, Messeter K, Nordström C-H: Cerebral vasoconstriction by indomethacin in intracranial hypertension. Anesthesiology 1995; 83:1283-1992

2. Biestro AA, Alberti RA, Soca AE, Cancela M, Puppo CB, Borovich B: Use of indomethacin in brain-injured patients with cerebral perfusion pressure impairment: Preliminary report. J Neurosurg 1995; 83:627-30

3. Dahl B, Bergholt B, Cold GE, Astrup J, Mosdal B, Jensen K, Kjærsgaard JO: $\rm CO_2$ and indomethacin vasoreactivity in patients with head injury. Acta Neurochir 1995, (In press)

4. Jensen K, Öhrström J, Cold GE, Astrup J: The effects of indomethacin on intracranial pressure, cerebral blood flow and cerebral metabolism in patients with severe head injury and intracranial hypertension. Acta Neurochir (Wien) 1991; 108:116-21

5. Asgeirsson B, Grände P-O, Nordström C-H: A new therapy of posttraumatic brain oedema based on transcapillary absorption via reduction of capillary hydrostatic pressure. Intensive Care 1994; 20:260-7

(Accepted for publication September 12, 1996.)

Anesthesiology 1996; 85:1501 © 1996 American Society of Anesthesiologists, Inc. Lippincott-Raven Publishers

Ultrasonography as an Aid to Internal Jugular Vein Cannulation: I

To the Editor: —Troianos et al.¹ used real-time ultrasonography with the Site Rite device (Dymax, Pittsburgh, PA) to clarify the relation between internal jugular vein and carotid artery in adults.¹

In this study, Polaroid photographs of the relevant images displayed on the screen of the Site Rite were taken with a modified camera, but 11.2% (127/1136) were subsequently rejected, partly because of poor image quality. There is an alternative method of data collection when using this device. It is simple, effective and inexpensive.

Transparent acetate sheets used with overhead projectors are cut into $6 \text{ cm} \times 4.5 \text{ cm}$ rectangles. One of these is then temporarily applied to the screen of the Site Rite device. The dimensions of the rectangle match that of the screen, and the housing of the screen holds it in place. Tilting of the device will add to stability, but adhesive is not needed. The anatomic structure under study is then surveyed by the investigator, and the relevant image is displayed on the screen. At this time, a co-investigator records relevant details from the screen image by drawing around salient images, recording them on the acetate rectangle with fine-tipped marker pens, which may be color-coded for clarity. The acetate is removed for study, and a new one

can then be applied. The shape, size, and relation of vessels are, thereby, easily recorded.

I concede that photography may be viewed as a "gold standard," but I believe the method I describe is an acceptable alternative. Problems of photographic lighting, costs of film, camera, and modifications are avoided, and accuracy is not sacrificed.

David R. Ball, M.B., B.S. (Lond), B.A. (Oxon), F.R.C.A. Aberdeen Royal Infirmary Foresterhill Aberdeen AB 9 2ZB UNITED KINGDOM

Reference

1. Troianos CA, Kuwik RJ, Pasqual JR, Lim AJ, Odasso DP: Internal jugular vein and carotid artery anatomic relation as determined by ultrasonography. Anesthesiology 1996; 85:43-8

(Accepted for publication September 21, 1996.)